Biogen's Alzheimer's Drug Leqembi Exceeds Sales Expectations

Despite initial slow uptake, Biogen's Leqembi sees a surge in sales and patient adoption, signaling growing momentum.

Biogen reports first-quarter Leqembi sales of $19 million, surpassing analyst expectations.
The number of patients on Leqembi nearly tripled since the end of 2023, with significant patient increases in March.
Medicare coverage and a $26,500 annual price tag define the drug's market dynamics.
Despite sales success, some U.S. doctors remain skeptical of Alzheimer's treatments, affecting broader adoption.
Biogen's overall strategy includes cost cuts and focus on newly launched drugs, aiming for sustained growth.